Biological Activity
Omidenepag is an EP2 receptor agonist for prostanoid signaling and ocular-cell research. Compared cellular bioenergetics, spheroid mechanics, lipid staining and gene expression.
In Vitro
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Orbital fibroblast model | Human orbital fibroblasts in 2D and 3D culture; omidenepag 100 nM, ripasudil 10 µM or combination. [1] | Compared cellular bioenergetics, spheroid mechanics, lipid staining and gene expression. |
| Metabolic response | 2D extracellular-flux measurements. [1] | Omidenepag shifted cells toward an energetic phenotype; ripasudil produced a more quiescent metabolic profile. |
| 3D mechanics | Orbital-fibroblast spheroids. [1] | Both treatments softened spheroids; extracellular-matrix and adipogenic marker responses differed. |
In Vivo
No compound-specific animal efficacy result is established by the sources summarized here.
Compound and Evidence Context
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Compound identity | Omidenepag versus omidenepag isopropyl. [1] | The study concerns the active compound; prodrug dosing or clinical eye-drop results are not transferred to this product. |
Interpretation
This product is omidenepag, not the isopropyl prodrug. Clinical eye-drop results for the prodrug are not directly assigned here.
